View Older Stories View More Recent Stories

Nov 3, 2022 04:30PM Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
Nov 3, 2022 04:30PM Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
Jul 28, 2022 08:00AM Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 28, 2022 08:00AM Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
May 13, 2022 08:30AM Vallon Pharmaceuticals Inc. (VLON) Prices 3.7M Share Offering at $1.06/sh
May 13, 2022 08:30AM Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
May 13, 2022 08:30AM Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
May 12, 2022 08:31AM Vallon Pharmaceuticals (VLON) Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30AM Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30AM Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 11, 2022 08:36AM Vallon Pharmaceuticals (VLON) Issued Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
May 11, 2022 08:35AM Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
May 11, 2022 08:35AM Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
May 9, 2022 04:05PM Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 9, 2022 04:05PM Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 22, 2022 08:02AM Vallon Pharmaceuticals Inc. (VLON) Announces Review of Strategic Alternatives
Apr 22, 2022 08:00AM Vallon Pharmaceuticals Announces Review of Strategic Alternatives
Apr 22, 2022 08:00AM Vallon Pharmaceuticals Announces Review of Strategic Alternatives
Mar 23, 2022 08:00AM Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
Mar 23, 2022 08:00AM Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
Mar 21, 2022 07:01AM Vallon Pharmaceuticals Inc. (VLON) Study for Lead Program, ADAIR, for the Treatment of ADHD Did Not Meet its Primary Endpoint
Mar 21, 2022 07:00AM Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
Mar 21, 2022 07:00AM Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
Feb 28, 2022 04:40PM Vallon Pharmaceuticals Inc. (VLON) Appoints Meenu Karson to its Board
Feb 28, 2022 04:05PM Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
Feb 28, 2022 04:05PM Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
Feb 28, 2022 08:05AM Vallon Pharmaceuticals (VLON) Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
Feb 28, 2022 08:05AM Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
Feb 28, 2022 08:05AM Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
Feb 14, 2022 04:15PM Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
Feb 14, 2022 04:15PM Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
Jan 20, 2022 08:35AM Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
Jan 20, 2022 08:35AM Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
Jan 18, 2022 08:05AM Vallon Pharmaceuticals Inc. (VLON) Reports New Data from Adult Stimulant Abuse Pattern Survey
Jan 18, 2022 08:05AM Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
Jan 18, 2022 08:05AM Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
Jan 12, 2022 10:35AM JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
Jan 4, 2022 08:05AM Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
Jan 4, 2022 08:05AM Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
Dec 23, 2021 08:05AM Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
Dec 23, 2021 08:05AM Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
Nov 12, 2021 08:05AM Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 12, 2021 08:05AM Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 11, 2021 08:05AM Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
Nov 11, 2021 08:05AM Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
Nov 10, 2021 08:35AM Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
Nov 10, 2021 08:35AM Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
Nov 4, 2021 02:30PM JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
Nov 1, 2021 08:35AM Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
Nov 1, 2021 08:35AM Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
View More Recent Stories View Older Stories